查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1931278

PMO偶联物市场按产品类型、应用、最终用户、递送方式和分子类型划分，全球预测，2026-2032年

PMO Conjugates Market by Product Type, Application, End User, Delivery Mode, Molecule Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，PMO 共轭物市场价值将达到 1.3285 亿美元，到 2026 年将成长至 1.5241 亿美元，到 2032 年将达到 3.4284 亿美元，复合年增长率为 14.50%。

主要市场统计数据
基准年 2025 1.3285亿美元
预计年份：2026年 1.5241亿美元
预测年份：2032年 3.4284亿美元
复合年增长率 (%) 14.50%

PMO偶联物的策略概述：重点关注治疗潜力、递送挑战、监管趋势和商业化管道，以相关人员。

磷酰二胺吗啉寡聚物(PMO) 偶联物的出现代表了反义疗法标靶递送领域的一项突破，它兼具分子精准性和高组织结合力。研发人员和相关人员正日益关注偶联策略如何能够在维持寡核苷酸活性的同时，改善其药物动力学和细胞摄取。同时，临床计画也持续改善病患入组标准和终点设计，以期证实其具有显着的治疗效果，尤其是在传统小分子和生技药品疗效有限的特定基因族群中。

新的技术、监管和商业性转折点将重塑PMO偶联疗法的全球开发和患者获取格局。

PMO偶联物领域正经历变革性的转折点，这主要得益于科学创新、不断变化的监管环境以及支付方和患者期望的转变。胜肽和抗体偶联化学的进步正在拓展工具箱，以改善细胞摄取、核内体逃脱和组织选择性，从而提高在难以到达的组织中实现持续靶向结合的可能性。同时，分析表征和基于平台的生产技术的改进正在简化CMC流程，使开发人员能够从客製化开发转向支援更广泛临床开发的标准化流程。

2025年美国关税政策预期变化对专案管理办公室（PMO）整合开发公司的供应链、成本结构和策略采购决策的影响

贸易政策和关税制度的预期变化可能会对复杂生技药品和寡核苷酸偶联物的原料采购、试剂成本和全球供应链经济产生重大影响。因此，开发PMO偶联物的公司应评估关税结构变化对供应商选择、库存策略和替代生产安排的影响。特别是，提高特殊试剂和中间体组件的进口关税可能会促使关键奖励的近岸外包或关键投入品的双重采购，从而减轻单一国家关税波动的影响。

详细的細項分析重点阐述了产品、应用、最终用户、给药途径和分子类型对研发重点和商业化路径的影响

了解这种细分市场的细微差别对于在PMO偶联物领域优先进行研发工作和进行商业性定位至关重要。根据产品类型，抗体-PMO偶联物和胜肽-PMO偶联物的研发路径有显着差异。基于抗体的构建体往往专注于透过受体介导靶向特定细胞群，而胜肽偶联物则可以进行模组化设计，以优化组织渗透性递送和细胞摄取。按应用领域划分，治疗重点集中在神经肌肉疾病、肿瘤和罕见遗传疾病，其中神经肌肉疾病的适应症进一步细分为Duchenne氏肌肉失养症和脊髓性肌肉萎缩症。在Duchenne氏肌肉失养症中，治疗方案的设计通常在跳跃外显子疗法和无义突变标靶疗法之间有所不同，每种疗法都有不同的患者纳入标准和监管先例。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和比较优势将决定临床检测实施和供应的韧性

区域趋势对PMO偶联物的临床开发策略、供应链设计和报销方式有显着影响。在美洲，完善的临床试验基础设施和对创新疗法较为开放的法规环境，有利于快速概念验证研究，并与支付方在基于价值的报销管道方面进行密切合作。在该地区运营的申办方通常会优先考虑早期与监管机构的沟通以及真实世界证据计划，以支持核准后的广泛应用。同时，欧洲、中东和非洲的市场环境较为复杂，各司法管辖区的监管协调程度不一，定价框架也存在差异，因此需要製定复杂的市场进入策略和量身定制的证据方案，以适应各国特定的卫生技术评估（HTA）流程。

竞争考察与合作并存的企业级洞察，揭示了PMO共轭生态系统中相关人员所采用的许可、伙伴关係和製造策略。

在PMO偶联物生态系统中，企业策略融合了竞争差异化和合作伙伴关係模式。早期创新者和学术衍生公司通常利用深厚的生物学知识和灵活的实验方法来主导药物发现和概念验证数据，从而确定目标的有效性。这些机构通常依赖与大型製药企业或专业的合约开发和生产组织（CDMO）的合作，以扩大其CMC（化学、生产和品管）营运规模，并推进到后期临床开发阶段。大型生物製药公司提供商业性专业知识、监管经验和成熟的分销网络。这些优势可以与创新的偶联平台结合，从而加速患者获得药物。

产业领导者可以采取哪些明确步骤来优化其PMO偶联物产品组合的研发产品线、供应链、监管回应和商业化？

产业领导者应充分发挥PMO偶联物的潜力，采取一系列切实可行的优先事项，将科学潜力与商业性可行性结合。首先，应优先考虑平台稳健性，投资于具有稳定分析性能和可扩展生产能力的连接子和偶联化学方法。这将降低下游监管的复杂性，并提高供应的可预测性。其次，应设计临床方案，在传统疗效终点之外，纳入可操作的持久性指标和患者报告获益，儘早为监管机构和支付方提供证据，并促进医保报销谈判。

调查方法详情：采用混合方法，结合定性和定量研究方法、专家检验和数据三角测量，以支持研究结果和建议。

本分析基于严谨的混合方法，结合了定性专家研究和权威第二手资料的定量综合分析。一手资讯来源包括对资深研发主管、生产专家、临床研究人员以及在寡核苷酸和偶联物项目方面拥有直接经验的监管顾问进行的结构化访谈。这些见解与对同行评审文献、监管指导文件和技术白皮书的深入审查相结合，以确保与当前的科学知识和先例保持一致。

一份策略建议综合报告，重点阐述了影响PMO偶联物应用、投资者兴趣和长期永续性的临床、营运和政策因素。

总之，PMO偶联物正处于一个转折点，标靶化和递送方面的科学进步与不断变化的监管政策和生产製造方面的营运创新相交。如果申办者能够使化学决策、临床策略和供应链韧性与监管机构和支付者的期望保持一致，那么这种疗法将为解决神经肌肉疾病、肿瘤和罕见遗传疾病领域尚未满足的医疗需求提供极具吸引力的机会。从产品类型、适应症、最终用户、给药方式和分子类型等方面进行策略性细分，有助于确定投资重点，并针对最有前景的患者群体优化研发管道。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的PMO偶联物市场

  • 抗体PMO偶联物
  • 胜肽PMO缀合物

9. 按应用分類的PMO共轭物市场

  • 神经肌肉疾病
    • Duchenne氏肌肉失养症
    • 脊髓性肌肉萎缩症
  • 肿瘤学
  • 罕见遗传疾病

第十章 依最终用户分類的PMO共轭物市场

  • 学术和研究机构
  • CRO（受託研究机构）
  • 製药和生物技术公司

11. 依交付方式分類的PMO偶联物市场

  • 肌肉内注射
  • 静脉注射
  • 皮下注射

12. 依分子类型分類的PMO偶联物市场

  • 多功能型
  • 单功能类型

第十三章 各地区PMO共轭物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的PMO共轭物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国PMO共轭物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国PMO共轭市场

第十七章：中国的PMO共轭市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Aurigene Pharmaceutical Services Ltd.
  • Avidity Biosciences, Inc.
  • Bio-Synthesis, Inc.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Creative Biogene Co., Ltd.
  • Epichem Pty Ltd
  • Gene Tools, LLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • NJ Bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche Holding AG
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-7B550E008E02

The PMO Conjugates Market was valued at USD 132.85 million in 2025 and is projected to grow to USD 152.41 million in 2026, with a CAGR of 14.50%, reaching USD 342.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 132.85 million
Estimated Year [2026] USD 152.41 million
Forecast Year [2032] USD 342.84 million
CAGR (%) 14.50%

Strategic overview of PMO conjugates highlighting therapeutic potential, delivery challenges, regulatory dynamics and commercialization pathways for stakeholders

The emergence of phosphorodiamidate morpholino oligomer (PMO) conjugates represents a pivotal advance in the targeted delivery of antisense therapies, blending molecular precision with enhanced tissue engagement. Developers and stakeholders are increasingly focused on how conjugation strategies transform pharmacokinetics and cellular uptake while preserving oligonucleotide activity. In parallel, clinical programs are refining patient selection criteria and endpoint design to demonstrate meaningful therapeutic benefit in genetically defined populations, particularly where conventional small molecules and biologics have limited efficacy.

Transitioning from laboratory validation to clinical translation requires coordinated attention to chemistry, manufacturing, controls, and regulatory interactions. Manufacturing scale-up presents unique demands because conjugation chemistries and linker technologies can introduce new analytical and stability considerations that influence lot-to-lot consistency. As a result, sponsors are adopting modular development plans that integrate analytical method development, bridging studies, and early engagement with regulatory authorities to de-risk pivotal programs. Taken together, these dynamics position PMO conjugates as a high-priority modality for precision therapeutics, while underscoring the need for cross-functional strategies that align R&D, regulatory, and commercial planning.

Emerging technological, regulatory and commercial inflection points reshaping the development and patient access landscape for PMO conjugate therapeutics globally

The PMO conjugate landscape is undergoing transformative shifts driven by convergence of scientific innovation, evolving regulatory frameworks, and changing payer and patient expectations. Advances in peptide and antibody conjugation chemistries have expanded the toolbox for improving cellular uptake, endosomal escape, and tissue selectivity, thereby elevating the probability of achieving durable target engagement in hard-to-reach tissues. At the same time, improvements in analytical characterization and platform-based manufacturing are streamlining CMC pathways, enabling sponsors to move from bespoke, case-by-case development toward more standardized processes that support broader clinical development.

Meanwhile, regulatory authorities are demonstrating greater familiarity with oligonucleotide modalities and are setting clearer expectations around toxicology, biodistribution, and long-term safety monitoring. This regulatory clarity is reducing uncertainty for clinical trial design and post-approval commitments, which in turn encourages greater investment in late-stage programs. Commercial models are also adapting: payers and health systems are increasingly weighing real-world evidence and durable benefit when assessing value, prompting sponsors to embed pragmatic outcomes measures and evidence-generation plans early in development. Because these shifts are interdependent, stakeholders that adopt integrated strategies across R&D, regulatory, manufacturing, and market access are positioned to capitalize on accelerating technological and policy momentum.

Projected implications of evolving United States tariff policies in 2025 on supply chains, cost structures, and strategic sourcing decisions for PMO conjugate developers

Anticipated changes in trade policy and tariff regimes can materially influence raw material sourcing, reagent costs, and the economics of global supply chains for complex biologics and oligonucleotide conjugates. Companies developing PMO conjugates should therefore evaluate how altered tariff structures may affect supplier selection, inventory strategies, and back-up manufacturing arrangements. In particular, higher import duties on specialty reagents or intermediate components can incentivize nearshoring of critical steps or the dual-sourcing of key inputs to mitigate exposure to single-country tariff shifts.

Beyond direct cost implications, tariffs influence strategic decisions about where to locate clinical manufacturing and fill-finish operations to preserve regulatory alignment and expedite investigational material supply. In this context, organizations are increasingly conducting scenario planning to understand how tariff changes interact with currency volatility, lead times, and the availability of qualified vendor capacity. By adopting a proactive approach to supply chain mapping and contract language, sponsors can maintain continuity of clinical programs and commercial launches even as trade policy evolves. This emphasizes the importance of cross-functional teams that regularly reassess supplier risk, contractual flexibility, and inventory buffers in light of potential policy changes.

Deep segmentation intelligence revealing how product, application, end user, delivery mode and molecule type influence development priorities and commercialization routes

A nuanced understanding of segmentation is essential to prioritize development efforts and commercial positioning across the PMO conjugate landscape. Based on product type, development pathways diverge significantly between antibody PMO conjugates and peptide PMO conjugates; antibody-based constructs often emphasize receptor-mediated targeting to specific cell populations, whereas peptide conjugates can be tailored for tissue-penetrant delivery and modular optimization of cellular uptake. Based on application, therapeutic priorities concentrate on neuromuscular diseases, oncology, and rare genetic disorders, with neuromuscular indications further differentiated into Duchenne muscular dystrophy and spinal muscular atrophy. Within Duchenne muscular dystrophy, program design commonly bifurcates between exon skipping therapies and approaches targeting nonsense mutations, each with distinct patient selection criteria and regulatory precedent.

Based on end user, development and translation pathways are shaped by the distinct incentives and capabilities of academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies; academic centers frequently drive early discovery and mechanistic studies, CROs enable scalable clinical development operations, and industry sponsors focus on late-stage evidence generation and market access. Based on delivery mode, clinical strategies reflect differences among intramuscular, intravenous, and subcutaneous administration, where route selection influences dosing frequency, patient convenience, and infrastructure requirements for trials and commercial distribution. Finally, based on molecule type, the field distinguishes between multi functional and single functional constructs, with multi functional molecules offering combinatorial benefits for targeting or activity and single functional designs emphasizing simplicity and manufacturability. Integrating these segmentation lenses allows sponsors to tailor preclinical models, CMC investments, and clinical endpoints to the most relevant patient populations and commercial pathways.

Regional dynamics and comparative advantages across the Americas, Europe Middle East & Africa and Asia-Pacific that determine clinical trial deployment and supply resilience

Regional dynamics exert a powerful influence on clinical development strategies, supply chain design, and reimbursement approaches for PMO conjugates. In the Americas, strong clinical trial infrastructure and a receptive regulatory environment for innovative modalities facilitate rapid proof-of-concept studies and close engagement with payers on value-based reimbursement pathways. Sponsors operating in this region often prioritize early regulatory interactions and real-world evidence planning to support broad access upon approval. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization across jurisdictions and diverse pricing frameworks require nuanced market access strategies and tailored evidence packages to align with country-specific HTA processes.

Asia-Pacific is characterized by growing research capabilities, expanding manufacturing capacity, and evolving regulatory pathways that increasingly accept science-driven dossiers for novel modalities. Companies targeting this region often pursue partnerships with local manufacturers and contract facilities to shorten supply chains and address regional demand. Across all regions, clinical trial site selection, patient recruitment dynamics, and local regulatory expectations should inform program timelines and operational investments. By aligning regional strategies with global development plans, sponsors can optimize resource allocation while maintaining the flexibility to adapt to jurisdiction-specific requirements and opportunities.

Competitive and collaborative company-level insights that illuminate licensing, partnership, and manufacturing strategies adopted by stakeholders in the PMO conjugate ecosystem

Company strategies within the PMO conjugate ecosystem reveal a mix of competitive differentiation and collaborative partnership models. Early-stage innovators and academic spinouts often drive discovery and proof-of-concept data, leveraging deep biological insight and nimble experimentation to establish target validity. These organizations typically rely on partnerships with larger pharmaceutical companies or specialized contract development and manufacturing organizations to scale CMC operations and navigate late-stage clinical development. Larger biopharma companies bring commercial expertise, regulatory experience, and access to established distribution networks, which can accelerate patient access when integrated with innovative conjugation platforms.

Contract research and manufacturing organizations play a pivotal role by offering modular capabilities that span analytical development, GMP manufacturing, and clinical supply logistics. Strategic alliances, licensing deals, and joint ventures are common themes as companies seek to combine complementary capabilities-novel conjugation chemistry from small innovators with global development infrastructure from established sponsors. Investors and strategic partners increasingly look for clarity around CMC readiness, reproducible analytical methods, and a credible plan for long-term safety monitoring as prerequisites for engagement. Overall, successful corporate strategies balance proprietary science with pragmatic partner selection and robust operational plans to de-risk development pathways.

Clear, actionable steps industry leaders can take to optimize R&D pipelines, supply chains, regulatory engagement and commercialization for PMO conjugate portfolios

Industry leaders should adopt a set of actionable priorities that bridge scientific potential and commercial execution to realize the promise of PMO conjugates. First, prioritize platform robustness by investing in linker and conjugation chemistries that demonstrate consistent analytical performance and scalable manufacturability; this reduces downstream regulatory complexity and improves the predictability of supply. Second, embed regulatory and payer evidence generation early by designing clinical programs that capture both traditional efficacy endpoints and pragmatic measures of durability and patient-reported benefit, thereby smoothing the pathway to reimbursement discussions.

Third, diversify supply chains by qualifying multiple vendors for critical reagents and establishing regional manufacturing options to reduce exposure to policy-driven disruptions. Fourth, pursue strategic collaborations that align scientific capabilities with operational scale, for example pairing academic discovery teams with experienced CMO partners and commercialization-focused sponsors. Fifth, refine clinical development strategies around delivery mode and patient convenience, as intramuscular, intravenous, and subcutaneous routes impose different clinical site and patient adherence considerations. By sequencing these actions and assigning clear internal ownership, organizations can reduce technical and commercial risks while accelerating time to patient impact.

Robust research methodology detailing the mixed qualitative and quantitative approaches, expert validation and data triangulation used to underpin findings and recommendations

This analysis is grounded in a rigorous mixed-methods approach that combines primary qualitative engagement with subject-matter experts and quantitative synthesis of authoritative secondary materials. Primary inputs include structured interviews with senior R&D leaders, manufacturing experts, clinical investigators, and regulatory advisors who have direct experience with oligonucleotide and conjugate programs. These insights were synthesized with deep-dive reviews of peer-reviewed literature, regulatory guidance documents, and technical white papers to ensure alignment with current scientific understanding and precedent.

Data triangulation and cross-validation steps were applied to reconcile differing perspectives and validate thematic findings. Where appropriate, analytical frameworks were used to map supply chains, identify critical control points in CMC, and assess clinical development risk. The methodology emphasizes transparency and replicability, with traceable evidence trails and documented assumptions that support the report's conclusions and recommendations. Expert review panels provided final validation to ensure that interpretations are actionable and reflective of real-world operational constraints.

Synthesis of strategic takeaways emphasizing clinical, operational and policy levers that influence adoption, investor interest and long-term viability of PMO conjugates

In summary, PMO conjugates stand at an inflection point where scientific advances in targeting and delivery converge with evolving regulatory clarity and operational innovations in manufacturing. The modality offers compelling opportunities to address unmet needs across neuromuscular diseases, oncology, and rare genetic disorders, provided that sponsors align chemistry decisions, clinical strategies, and supply chain resilience with regulatory and payer expectations. Strategic segmentation that considers product type, application, end user, delivery mode, and molecule type helps prioritize investments and tailor development pathways to the most promising patient populations.

Practical next steps for stakeholders include strengthening platform reproducibility, engaging regulators and payers earlier in the development cycle, and establishing diversified manufacturing and sourcing strategies to mitigate policy and operational risks. By executing an integrated approach that harmonizes scientific rigor with pragmatic commercialization planning, organizations can enhance the likelihood of successful translation from bench to bedside while delivering meaningful clinical benefit to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PMO Conjugates Market, by Product Type

  • 8.1. Antibody PMO Conjugates
  • 8.2. Peptide PMO Conjugates

9. PMO Conjugates Market, by Application

  • 9.1. Neuromuscular Diseases
    • 9.1.1. Duchenne Muscular Dystrophy
    • 9.1.2. Spinal Muscular Atrophy
  • 9.2. Oncology
  • 9.3. Rare Genetic Disorders

10. PMO Conjugates Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical & Biotechnology Companies

11. PMO Conjugates Market, by Delivery Mode

  • 11.1. Intramuscular
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. PMO Conjugates Market, by Molecule Type

  • 12.1. Multi Functional
  • 12.2. Single Functional

13. PMO Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. PMO Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. PMO Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States PMO Conjugates Market

17. China PMO Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Aurigene Pharmaceutical Services Ltd.
  • 18.8. Avidity Biosciences, Inc.
  • 18.9. Bio-Synthesis, Inc.
  • 18.10. Biogen Inc.
  • 18.11. BioMarin Pharmaceutical Inc.
  • 18.12. Creative Biogene Co., Ltd.
  • 18.13. Epichem Pty Ltd
  • 18.14. Gene Tools, LLC
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. NJ Bio, Inc.
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. PTC Therapeutics, Inc.
  • 18.21. Roche Holding AG
  • 18.22. Sarepta Therapeutics, Inc.
  • 18.23. Wave Life Sciences Ltd.
  • 18.24. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PMO CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PMO CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PMO CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PMO CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PMO CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PMO CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PMO CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. GCC PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. G7 PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. NATO PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NATO PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)